Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elezanumab in Acute Traumatic Cervical Spinal Cord Injury
jRCT2031210009Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in acute cervical spinal cord injury (ACSCI) comparing Elezanumab IV with Placebo IV (2 arms). Primary endpoint: Upper Extremity Motor Score at 52 Weeks. Started Nov 2020; status: active, not recruiting.
02
Drugs
elezanumab
03
Conditions
acute cervical spinal cord injury (ACSCI)
Beyond the preview
Go deeper on jRCT2031210009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210009.